Loading
IP
Infinity Pharmaceuticals, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by BVF PARTNERS L P/IL, was filed 17 Dec 2018.
Infinity Pharmaceuticals, Inc.: what insiders have been doing
This page follows insider dealings at Infinity Pharmaceuticals, Inc. as filed with SEC (Form 4), a company from the Healthcare & Pharma sector. Infinity Pharmaceuticals, Inc. has had no insider filing for more than a year; the last one goes back to 12 September 2023.
Looking back to 2016, when coverage begins, insiders filed 58 purchases and 18 sales.
Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Insider Decl.
113
Thresholds
n/a
Buy Volume
€16M
58 ops. · all time
Sell Volume
€30M
18 ops. · all time
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2022FY ended December 2022 · cache
Income statement
RevenueUS$2.2M
Net income-US$38.2M-1711.1% margin
Last declaration on 12 September 2023
Declarations113 total
410,196 shares@ US$0.0753.2% of flowCommon StockSEC:0000899243-23-018762:1
768,133 sharesCommon StockSEC:0000899243-23-018762:0
14,994 shares@ US$0.6624100.0% of flowCommon StockSEC:0001140361-22-028234:1
50,000 sharesCommon StockSEC:0001140361-22-028234:0
46,378 shares@ US$0.67977.6% of flowCommon StockSEC:0001140361-22-023338:0
30,919 shares@ US$0.679100.0% of flowCommon StockSEC:0001140361-22-023308:0
3,061 shares@ US$3.4322.4% of flowCommon StockSEC:0001140361-21-020643:0
3,061 shares@ US$3.43100.0% of flowCommon StockSEC:0001140361-21-020650:0
5,000 shares@ US$0.92100.0% of flowCommon StockSEC:0001140361-21-017889:0
1,215,491 shares@ US$5.368612.0% of flowCommon Stock, $0.001 par valueSEC:0000921895-21-000479:0
892,467 shares@ US$5.36868.8% of flowCommon Stock, $0.001 par valueSEC:0000921895-21-000479:1
152,127 shares@ US$5.36861.5% of flowCommon Stock, $0.001 par valueSEC:0000921895-21-000479:2
2,821,663 shares@ US$4.138821.4% of flowCommon Stock, $0.001 par valueSEC:0000921895-21-000161:0
2,458,838 shares@ US$4.138818.7% of flowCommon Stock, $0.001 par valueSEC:0000921895-21-000161:1
568,019 shares@ US$4.13884.3% of flowCommon Stock, $0.001 par valueSEC:0000921895-21-000161:2
22,826 shares0Common StockSEC:0000899243-20-016999:0
64,219 shares0Common StockSEC:0000899243-20-001081:0
53,538 shares0Common StockSEC:0000899243-20-001083:0
83,157 shares0Common StockSEC:0000899243-20-001082:0
155,134 shares0Common StockSEC:0000899243-20-001080:0
13,125 shares@ US$1.6025.1% of flowCommon StockSEC:0000899243-19-017006:0
26,250 shares@ US$1.6052.2% of flowCommon StockSEC:0000899243-19-016999:0
54,461 shares@ US$1.19950.5% of flowCommon Stock, $0.001 par valueSEC:0000921895-18-003336:0
Canonical exit: 13 Mar 2019 (T+90)
120,539 shares@ US$1.19951.1% of flowCommon Stock, $0.001 par valueSEC:0000921895-18-003336:1
Canonical exit: 13 Mar 2019 (T+90)
100,000 shares@ US$1.300.9% of flowCommon Stock, $0.001 par valueSEC:0000921895-18-003181:0
Canonical exit: 26 Feb 2019 (T+90)
25 of 113 declarations
About Infinity Pharmaceuticals, Inc.
Infinity Pharmaceuticals, Inc. (ticker: INFI) is a United States biotechnology company listed on the Nasdaq market. The company was historically headquartered in Cambridge, Massachusetts, and was founded in 1995. Over time, Infinity built its identity as a clinical-stage oncology developer focused on novel, mechanism-driven drug discovery. In recent years, however, the company has gone through a significant strategic reset, including a shrinking operating footprint and the collapse of its proposed merger with MEI Pharma in 2023. For investors, INFI should therefore be viewed as a small-cap biotech with a high-risk profile, limited commercial scale, and a highly event-driven equity story.
Infinity’s core business has centered on developing innovative cancer therapies. Its best-known program was eganelisib (IPI-549), an oral PI3K-gamma inhibitor designed to reprogram macrophages within the tumor microenvironment. That scientific approach positioned Infinity as a differentiated immuno-oncology player, with the goal of creating value through targeted biology rather than through a broad commercial franchise. In practice, however, the company’s development track record has been challenged by the usual biotech risks: clinical uncertainty, limited resources, and the difficulty of translating promising mechanisms into durable late-stage value.
Read moreShow less
From a competitive standpoint, Infinity operated in one of the most crowded and capital-intensive segments of the healthcare sector. It competed indirectly with large pharmaceutical companies, better-funded oncology specialists, and numerous early-stage biotech peers pursuing similar immune-oncology opportunities. As a result, Infinity’s competitive strength was never scale; it was the possibility of scientific differentiation, intellectual property, and optionality around its pipeline assets. That makes the stock more sensitive to pipeline updates, regulatory events, and financing or strategic announcements than to ordinary operating momentum.
Geographically, the company’s activities were centered in the United States, with its historical base in Cambridge, Massachusetts, a major biotech hub. This location gave Infinity access to scientific talent, research infrastructure, and industry networks, but the company remained fundamentally a U.S.-focused development organization rather than a diversified global pharmaceutical platform.
Recent corporate developments have been important for the equity narrative. In July 2023, Infinity announced the termination of its merger agreement with MEI Pharma. Since then, the market has focused mainly on the company’s capital structure, governance, and SEC disclosures, including Form 4 insider transaction filings. That regulatory backdrop matters for investors because it underscores how much of the remaining investment case is driven by corporate actions, ownership changes, and asset optionality rather than a broad commercial product base.
Overall, INFI represents a highly speculative Nasdaq-listed biotechnology name in the United States, with historical oncology assets, a scientifically focused but constrained business model, and limited visibility on long-term operating performance.
